These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33880062)

  • 21. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individual, Area, and Provider Characteristics Associated With Care Received for Stages I to III Breast Cancer in a Multistate Region of Appalachia.
    Kimmick GG; Camacho F; Mackley HB; Kern T; Yao N; Matthews SA; Fleming S; Lipscomb J; Liao J; Hwang W; Anderson RT
    J Oncol Pract; 2015 Jan; 11(1):e9-e18. PubMed ID: 25228530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Felix AS; McLaughlin EM; Caan BJ; Cohn DE; Anderson GL; Paskett ED
    Int J Cancer; 2020 Jul; 147(2):404-412. PubMed ID: 31618444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
    Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
    Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
    Statler AB; Hobbs BP; Wei W; Gupta A; Blake CN; Nahleh ZA
    Sci Rep; 2019 Dec; 9(1):18126. PubMed ID: 31792304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
    Fang P; He W; Gomez DR; Hoffman KE; Smith BD; Giordano SH; Jagsi R; Smith GL
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):748-757. PubMed ID: 28366580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
    BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
    Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
    Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
    Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variations in Guideline-Concordant Breast Cancer Adjuvant Therapy in Rural Georgia.
    Guy GP; Lipscomb J; Gillespie TW; Goodman M; Richardson LC; Ward KC
    Health Serv Res; 2015 Aug; 50(4):1088-108. PubMed ID: 25491350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States.
    Tchelebi LT; Shen B; Wang M; Potters L; Herman J; Boffa D; Segel JE; Park HS; Zaorsky NG
    Adv Radiat Oncol; 2022; 7(5):100938. PubMed ID: 35469182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population.
    Lin S; Mo H; Li Y; Guan X; Chen Y; Wang Z; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Front Oncol; 2021; 11():670723. PubMed ID: 34046360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer.
    Bastiaannet E; Charman J; Johannesen TB; Schrodi S; Siesling S; van Eycken L; Walsh PM; Audisio RA; Boelens PG; Rubio IT; Jones N; Lewis J; van de Velde CJH
    Clin Breast Cancer; 2018 Aug; 18(4):e613-e619. PubMed ID: 29275865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.
    Denu RA; Hampton JM; Currey A; Anderson RT; Cress RD; Fleming ST; Lipscomb J; Sabatino SA; Wu XC; Wilson JF; Trentham-Dietz A
    Cancer Epidemiol; 2016 Feb; 40():7-14. PubMed ID: 26605428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer.
    Sabatino SA; Thompson TD; Wu XC; Fleming ST; Kimmick GG; Trentham-Dietz A; Cress R; Anderson RT
    Breast Cancer Res Treat; 2014 Jul; 146(1):199-209. PubMed ID: 24899083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.